{"entity":{"id":"opb-401","kind":"drug","name":"OPB-401","aka":[],"tldr":"OPB-401 is an experimental in vivo CAR T-cell therapy from Outpace Bio, in preclinical development for B-cell lymphomas.","summary":"OPB-401 is an in vivo CAR T-cell therapy from Outpace Bio. An in vivo CAR-T programme against CD19 and CD20; the source gives no further detail. Its furthest stage is preclinical development, for B-cell lymphomas. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Outpace Bio: outpacebio.com","url":"https://outpacebio.com/our-science"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["cd19","cd20"],"drugs":[],"companies":["outpace-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"OPB-401","modality":"In vivo CAR T-cell therapy","mechanism":"An in vivo CAR-T programme against CD19 and CD20; the source gives no further detail.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/opb-401/","neighbours":{"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"outpace-bio","kind":"company","name":"Outpace Bio","route":"/companies/outpace-bio/"}]}}